Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review.
Naqvi SAA, Anjum MU, Bibi A, Khan MA, Khakwani KZR, He H, Imran M, Kazmi SZ, Raina A, Cobran EK, Bryan Rumble R, Oliver TK, Agarwal N, Zakharia Y, Taplin ME, Sartor O, Singh P, Orme JJ, Childs DS, Parikh RA, Garje R, Murad MH, Bryce AH, Riaz IB.
Naqvi SAA, et al.
medRxiv [Preprint]. 2025 Apr 16:2025.04.15.25325837. doi: 10.1101/2025.04.15.25325837.
medRxiv. 2025.
PMID: 40321256
Free PMC article.
Preprint.
CONCLUSION: Findings from the current LSR suggest that optimal treatment for mCRPC should be individualized based on prior therapy and HRR alterations. Current evidence favors PARPi alone (ARPI exposed) or in combination with ARPI (ARPI naive) for patients with BRCA altera …
CONCLUSION: Findings from the current LSR suggest that optimal treatment for mCRPC should be individualized based on prior therapy and HRR a …